[특허]Modulators of coagulation factors with enhanced stability

Modulators of coagulation factors with enhanced stability 원문보기

IPC분류정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	C12Q-001/68 C12N-005/00 A01N-043/04 A01N-043/02 C07H-021/02 C07H-021/00 C07H-021/04
출원번호	UP-0546190 (2006-10-11)
등록번호	US-7531524 (2009-07-01)
발명자 / 주소	Rusconi, Christopher P.
출원인 / 주소	Regado Biosciences, Inc.
인용정보	피인용 횟수 : 0 인용 특허 : 96

초록 ▼

The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host unde

대표청구항 ▼

The invention claimed is: 1. A composition comprising a nucleic acid sequence of one of SEQ ID NOs. 19, 39, and 55-59 linked to a polyethylene glycol molecule at a 5' terminus via a linker moiety, or a pharmaceutically acceptable salt thereof. 2. The composition of claim 1 of the formula: wherein ligand is selected from one of SEQ ID NO. 19, 39, or 55-59 or a pharmaceutically acceptable salt thereof. 3. The composition of claim 1 wherein the composition is produced by conjugating a linker precursor to a nucleic acid molecule to form a nucleic acid linker-composition and further, conjugating a polyethylene glycol precursor moiety to the linker of the nucleic acid-linker composition. 4. The composition of claim 3 in which the linker precursor is selected from the group consisting of: 6-(trifluoroacetamido)hexanol (2-cyanoethyl-N,N-diisopropyl)phosphoramidite of the structure: TFA-amino C4 CED phosphoramidite of the structure: 5'-amino modifier C3 TFA of the structure: 5'-amino modifier 5 of the structure: 5'-amino modifier C12 of the structure: and 5'thiol-modifier C6 of the structure: 5. The composition of claim 3 wherein the polyethylene glycol precursor is selected from: 6. The composition of claim 1 wherein the polyethylene glycol has a total mass of about 40 kD. 7. The composition of claim 1 wherein the composition comprises two polyethylene glycol moieties. 8. The composition of claim 7 wherein each moiety has a total mass of about 20 kD. 9. The composition of claim 1 wherein the nucleic acid comprises SEQ ID NO: 19. 10. The composition of claim 1 wherein the nucleic acid comprises SEQ ID NO: 39. 11. The composition of claim 1 comprising the structure: 5'-O-[6-[N2-(monomethoxy 20K polyethylene glycol carbamoyl)-N6-(monomethoxy 20K polyethylene glycol carbamoyl)]-lysylamido]hexyl]-2'-methoxy-2'-deoxguanylyl-(3'-5')-2'-methoxy-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxcytidylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-methoxy-2'-deoxyuridylyl-(3'-5')-riboguanylyl-(3'-5')-2'-methoxy-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxcytidylyl-(3'-5')-2'-methoxy-2'-deoxytidylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-methoxy-2'-deoxcytidylyl-(3'-3')-thymidine. 12. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 13. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 14. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 15. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 16. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 17. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 18. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 19. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 20. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 21. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 22. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 23. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 24. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 25. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 26. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 27. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 28. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 29. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 30. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 31. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 32. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 33. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 34. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 35. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 36. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 37. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 38. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 39. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 40. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 41. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 42. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 43. The composition of claim 1 of the formula: or a pharmaceutically acceptable salt thereof. 44. A method of regulating blood coagulation comprising contacting a Factor IXa molecule with a composition comprising a nucleic acid sequence of one of SEQ ID NOs. 19, 39, and 55-59 linked to a polyethylene glycol molecule at a 5' terminus via a linker moiety, or a pharmaceutically acceptable salt thereof. 45. The method of claim 44 wherein the nucleic acid sequence is an aptamer that comprises the structure: 5'-O-[6-[N2-(monomethoxy 20K polyethylene glycol carbamoyl)-N6-(monomethoxy 20K polyethylene glycol carbamoyl)]-lysylamido]hexyl]-2'-methoxy-2'-deoxguanylyl-(3'-5')-2'-methoxy-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxyguanylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-methoxy-2'-deoxyuridylyl-(3'-5')-riboguanylyl-(3'-5')-2'-methoxy-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxycytidylyl-(3'-5')-2'-fluoro-2'-deoxyuridylyl-(3'-5')-2'-methoxy-2'-deoxcytidylyl-(3'-5')-2'-methoxy-2'-deoxytidylyl-(3'-5')-2'-methoxy-2'-deoxyadenylyl-(3'-5')-2'-methoxy-2'-deoxcytidylyl-(3'-3')-thymidine, or a pharmaceutically acceptable salt thereof. 46. The method of claim 44 further comprising contacting the composition with an antidote oligonucleotide.

이 특허에 인용된 특허 (96)

Cook Phillip Dan ; Kawasaki Andrew Mamoru, 2'-O-modified oligonucleotides.
상세보기
Cook Phillip Dan ; Kawasaki Andrew Mamoru, 2'-modified oligonucleotides.
상세보기
Cook Phillip Dan ; Kawasaki Andrew Mamoru, 2'-modified oligonucleotides.
상세보기
Cook, Phillip Dan; Kawasaki, Andrew Mamoru, 2'modified oligonucleotides.
상세보기
Green Michael R. (Boylston MA) Zapp Maria L. (Boylston MA) Stern Seth (Sterling MA), 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding.
상세보기
Dudycz Lech ; Matulic-Adamic Jasenka ; Beigelman Leonid, Amido and peptido modified enzymatic nucleic acid molecules.
상세보기
Monia Brett P. ; Cowsert Lex M., Antisense modulation of ubiquitin protein ligase expression.
상세보기
Toole John J. ; Griffin Linda C. ; Bock Louis C. ; Latham John A., Aptamer analogs specific for biomolecules.
상세보기
Griffin Linda ; Albrecht Glenn ; Latham John ; Leung Lawrence ; Vermaas Eric ; Toole John J., Aptamers specific for biomolecules and methods of making.
상세보기
Benseler Fritz,DEX ; Cole James L. ; Olsen David B. ; Kuo Lawrence C., Capped synthetic RNA, analogs, and aptamers.
상세보기
Benseler Fritz,DEX ; Cole James L. ; Olsen David B. ; Kuo Lawrence C., Capped synthetic RNA, analogs, and aptamers.
상세보기
Massie ; II Johnny Dale ; Massie Jean Marie ; Stafford Donald Wayne ; Wallin Peter Eric, Caprolactone ester polyurethane developer roller.
상세보기
Takei Yoshiyuki,JPX ; Maruyama Atsushi,JPX ; Akaike Toshihiro,JPX ; Kawano Sunao,JPX ; Okumura Shigetoshi,JPX ; Nogawa Masayuki,JPX ; Asayama Shoichiro,JPX, Carriers targettable to organ.
상세보기
Bracht Franzpeter,DEX ; Schror Karsten,DEX, Cathepsin G-inhibiting aptamers.
상세보기
Coutts Stephen M. (Rancho Santa Fe CA) Jones David S. (San Diego CA) Livingston Douglas A. (San Diego CA) Yu Lin (San Diego CA), Chemically-defined non-polymeric valency platform molecules and conjugates thereof.
상세보기
Coutts Stephen M. (Rancho Santa Fe CA) Jones David S. (San Diego CA) Livingston Douglas A. (San Diego CA) Yu Lin (San Diego CA), Chemically-defined non-polymeric valency platform molecules and conjugates thereof.
상세보기
Coutts Stephen M. ; Barstad Paul A. ; Iverson G. Michael ; Jones David S., Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule.
상세보기
Hirsh Jack,CAX ; Weitz Jeffrey I.,CAX, Compositions and methods for inhibiting thrombogenesis.
상세보기
Alexander Petr ; Prisbe Ernest J., Compounds and methods for making and using same.
상세보기
Gold Larry (Boulder CO) Tasset Diane (Boulder CO 4), DNA ligands of thrombin.
상세보기
Manoharan Muthiah ; Cook Phillip Dan ; Bennett Clarence Frank, Derivatized oligonucleotides having improved uptake and other properties.
상세보기
Skouv Jan,DKX ; Fenger Mogens,DKX ; Jacobsen Mogens Havsteen,DKX, Detection of mutations in genes by specific LNA primers.
상세보기
Bruice Thomas W. (Carlsbad CA) Lima Walter F. (San Diego CA), Determination of oligonucleotides for therapeutics, diagnostics and research reagents.
상세보기
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
상세보기
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
상세보기
Joyce Gerald F. ; Breaker Ronald R., Enzymatic DNA molecules.
상세보기
Barbas Carlos F. ; Joyce Gerald ; Santoro Stephen W. ; Kandasamy Sakthivel, Enzymatic DNA molecules that contain modified nucleotides.
상세보기
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
상세보기
Schneider Daniel J. ; Vanderslice Rebecca ; Gold Larry, Flow cell SELEX.
상세보기
Castro Stephanie L. ; Barbera-Guillem Emilio, Functionalized nanocrystals and their use in detection systems.
상세보기
Takle Garry B. ; George Shaji T., Heme-bearing microparticles for targeted delivery of drugs.
상세보기
Janjic Nebojsa ; Gold Larry ; Tasset Diane, High affinity ligands of basic fibroblast growth factor and thrombin.
상세보기
Pieken Wolfgang (Longmont CO) Tasset Diane (Boulder CO) Janjic Nebojsa (Lafayette CO) Gold Larry (Boulder CO) Kirschenheuter Gary P. (Arvada CO), High affinity nucleic acid ligands containing modified nucleotides.
상세보기
Pieken Wolfgang ; Tasset Diane ; Janjic Nebojsa ; Gold Larry ; Kirschenheuter Gary P., High affinity nucleic acid ligands containing modified nucleotides.
상세보기
Nieuwlandt Dan T. (Boulder CO) Gold Larry (Boulder CO) Wecker Matthew (Boulder CO), High-affinity oligonucleotide ligands to the tachykinin substance P.
상세보기
Hosel Wolfgang,DEX ; Mutter Wolfgang,DEX, Homogeneous detection methods for the determination of subpopulations of an analyte.
상세보기
Jayasena Sumedha ; Gold Larry, Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction.
상세보기
Jayasena Sumedha ; Gold Larry, Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction.
상세보기
Schumacher Antonius Nicolass Maria ; Kim Peter S., Identification of enantiomeric ligands.
상세보기
Brent Roger ; McCoy John M. ; Jessen Timm H.,DEX, Interaction trap systems for detecting protein interactions.
상세보기
Gold Larry (Boulder CO) Tasset Diane (Boulder CO), Ligands of thrombin.
상세보기
Bodenhamer William T., Method and apparatus for selective biological material detection.
상세보기
Gold Larry ; Tuerk Craig, Method for detecting a target molecule in a sample using a nucleic acid ligand.
상세보기
Toole John J. (Burlingame CA) Latham John (Palo Alto CA) Bock Louis C. (Foster City CA) Griffin Linda C. (Atherton CA), Method for identifying an oligonucleotide aptamer specific for a target.
상세보기
Eric Rose ; David Stern ; Ann Marie Schmidt ; Talia Spanier, Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation.
상세보기
Rose Eric ; Stern David ; Schmidt Ann Marie ; Spanier Talia, Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation.
상세보기
Schmidt Francis J. ; Cho Bongrae,KRX ; Nicholas ; Jr. Hugh B., Method for obtaining RNA aptamers based on shape selection.
상세보기
Sampson Jeffrey R. ; Dellinger Douglas J., Method of amplifying the signal of target nucleic acid sequence analyte.
상세보기
Kauffman Stuart Alan ; Ballivet Marc,CHX, Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and co.
상세보기
Li Weihua, Method of isolating target specific oligonucleotide ligands.
상세보기
Alul Rushdi (Columbia MD), Methods and compositions for sequence-specific hybridization of RNA by 2′-5′oligonucleotides.
상세보기
Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Methods for identifying nucleic acid ligands.
상세보기
Pinsky David J. ; Stern David ; Schmidt Ann Marie ; Rose Eric ; Solomon Robert A., Methods for treating an ischemic disorder and improving stroke outcome.
상세보기
Pinsky David J. ; Stern David ; Schmidt Ann Marie ; Rose Eric A. ; Connolly E. Sander ; Solomon Robert A. ; Prestigiacomo Charles J., Methods for treating an ischemic disorder and improving stroke outcome.
상세보기
Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Methods of producing nucleic acid ligands.
상세보기
Gold Larry ; Tuerk Craig, Methods of producing nucleic acid ligands.
상세보기
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
상세보기
Swaminathan Sundaramoorthi ; Matteucci Mark ; Pudlo Jeff ; Jones Robert J., Modified internucleoside linkages (II).
상세보기
Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
상세보기
Wong Chi-Huey ; Hendrix Martin,DEX ; Alper Phil ; Priestley E. Scott, Nucleic acid binders having an hydroxyamine motif.
상세보기
Eckstein Fritz,DEX ; Heaton Paul A.,GBX ; Vaish Narendra K., Nucleic acid catalysts with endonuclease activity.
상세보기
Gold Larry ; Schmidt Paul G ; Janjic Nebojsa, Nucleic acid ligand complexes.
상세보기
Gold Larry ; Schmidt Paul G. ; Janjic Nebojsa, Nucleic acid ligand complexes.
상세보기
Jayasena Sumedha ; Gold Larry, Nucleic acid ligand inhibitors to DNA polymerases.
상세보기
Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Nucleic acid ligands.
상세보기
Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Nucleic acid ligands.
상세보기
Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Nucleic acid ligands.
상세보기
Gold Larry ; Tuerk Craig, Nucleic acid ligands.
상세보기
Gold Larry ; Tuerk Craig, Nucleic acid ligands.
상세보기
Stephens Andrew ; Gold Larry ; Speck Ulrich,DEX, Nucleic acid ligands of tissue target.
상세보기
Korman Alan J. ; Gold Larry, Nucleic acid ligands to CD40ligand.
상세보기
Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (San Francisco CA), Nucleosides useful in the preparation of polynucleotides.
상세보기
Stanley Christopher John,GBX ; Weber Anders,DKX, Optical sensor for in situ measurement of analytes.
상세보기
Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Boulder CO), Phosphoramidite compounds and processes.
상세보기
Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Phosphoramidite nucleoside compounds.
상세보기
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
상세보기
Caruthers Marvin H. (Boulder CO) Brill Wolfgang K.-D. (Schopfheim DEX) Yau Eric (Mercer Island WA) Ma Michael (New York NY) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate compounds.
상세보기
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO), Polynucleotide phosphorodithioates.
상세보기
Gibbs Craig S. ; Leung Lawrence L. K. ; Tsiang Manuel, Polypeptides and coagulation therapy.
상세보기
Caruthers Marvin H. (Boulder CO) Beaucage Serge L. (Mountain View CA), Process for oligonucleo tide synthesis using phosphormidite intermediates.
상세보기
Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
상세보기
Caruthers Marvin H. (Boulder CO) Matteucci Mark D. (Boulder CO), Process for preparing polynucleotides.
상세보기
Kauffman Stuart Alan ; Ballivet Marc,CHX, Process for the production of stochastically-generated transcription or translation products.
상세보기
Cook Phillip Dan ; Springer Robert H. ; Sprankle Kelly G. ; Ross Bruce S., Process for the synthesis of 2'-O-substituted pyrimidines.
상세보기
Cook Phillip Dan ; Sanghvi Yogesh S. ; Sprankle Kelly G. ; Ross Bruce S. ; Griffey Rich H. ; Springer Robert H., Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom.
상세보기
Essigmann John M. ; Croy Robert G. ; Chen Zhenghuan, Programmable genotoxic agents and uses therefor.
상세보기
Essigmann John M. ; Croy Robert G. ; Yarema Kevin J. ; Morningstar Marshall, Programmable genotoxic agents and uses therefor.
상세보기
Nadeau James G. ; Vogler Erwin A., Rapidly reversed thrombin binding oligonucleotide anticoagulants.
상세보기
Arnold Frances H. ; Shao Zhixin ; Affholter Joseph A. ; Zhao Huimin ; Giver Lorraine J., Recombination of polynucleotide sequences using random or defined primers.
상세보기
Arnold Frances H. ; Shao Zhixin ; Affholter Joseph A. ; Zhao Huimin H ; Giver Lorraine J., Recombination of polynucleotide sequences using random or defined primers.
상세보기
Collins Mark L. (Walnut Creek CA) Horn Thomas (Berkeley CA) Sheridan Patrick J. (San Leandro CA) Warner Brian D. (Martinez CA) Urdea Michael S. (Alamo CA), Reduction of nonspecific hybridization by using novel base-pairing schemes.
상세보기
Collins Mark L. ; Horn Thomas ; Sheridan Patrick J. ; Warner Brian D. ; Urdea Michael S., Reduction of nonspecific hybridization by using novel base-pairing schemes.
상세보기
Cech Thomas R. (Boulder CO) Herschlag Daniel (Boulder CO), Site specific cleavage of single-stranded DNA.
상세보기
Green Michael R. ; Zapp Maria L., Small molecule inhibition of RNA/ligand binding.
상세보기
Cook Phillip Dan (Carlsbad CA) Kawasaki Andrew Mamoro (Oceanside CA), Sugar modified oligonucleotides that detect and modulate gene expression.
상세보기
Biesecker Greg ; Jayasena Sumedha D. ; Gold Larry ; Smith Drew ; Kirschenheuter Gary, Systematic evolution of ligands exponential enrichment: blended selex.
상세보기

IPC	Description
A	생활필수품
A62	인명구조; 소방(사다리 E06C)
A62B	인명구조용의 기구, 장치 또는 방법(특히 의료용에 사용되는 밸브 A61M 39/00; 특히 물에서 쓰이는 인명구조 장치 또는 방법 B63C 9/00; 잠수장비 B63C 11/00; 특히 항공기에 쓰는 것, 예. 낙하산, 투출좌석 B64D; 특히 광산에서 쓰이는 구조장치 E21F 11/00)
A62B-1/08	.. 윈치 또는 풀리에 제동기구가 있는 것

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Modulators of coagulation factors with enhanced stability 원문보기

초록 ▼

대표청구항 ▼

연구과제 타임라인

이 특허에 인용된 특허 (96)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

연합인증

Modulators of coagulation factors with enhanced stability 원문보기

초록 ▼

대표청구항 ▼

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

이 특허에 인용된 특허 (96)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트